Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma
Fick C, Dunne E, Sihag S, Molena D, Cytryn S, Janjigian Y, Wu A, Worrell S, Hofstetter W, Jones D, Gray K. Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma. The Annals Of Thoracic Surgery 2024, 118: 130-140. PMID: 38408631, PMCID: PMC11194153, DOI: 10.1016/j.athoracsur.2024.02.021.Peer-Reviewed Original ResearchLocally advanced esophagealImmune checkpoint inhibitorsDisease-free survivalGastroesophageal junctionPerioperative immunotherapyAdvanced esophagealNeoadjuvant chemoradiotherapyEsophageal carcinomaLocally advanced esophageal carcinomaPooled adverse event rateLocally advanced esophageal cancerPathologic complete response rateResponse rateDual checkpoint inhibitionGastroesophageal junction carcinomaAdvanced esophageal carcinomaComplete response rateAdvanced esophageal cancerEsophageal squamous cell carcinomaGastroesophageal junction cancerR0 resection rateResectable esophageal carcinomaPhase III trialsSquamous cell carcinomaAdverse event ratesThe Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
Dunne E, Fick C, Isbell J, Chaft J, Altorki N, Park B, Spicer J, Forde P, Gomez D, Iyengar P, Harpole D, Stinchcombe T, Liberman M, Bott M, Adusumilli P, Huang J, Rocco G, Jones D. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer. The Annals Of Thoracic Surgery 2024, 118: 119-129. PMID: 38316378, PMCID: PMC11194155, DOI: 10.1016/j.athoracsur.2024.01.024.Peer-Reviewed Original ResearchResected non-small cell lung cancerNon-small cell lung cancerAdvanced non-small cell lung cancerImmune checkpoint inhibitorsPhase III trialsCell lung cancerICI therapyPerioperative immunotherapyIII trialsLocally advanced non-small cell lung cancerTreatment of resectable non-small cell lung cancerLung cancerLong-term survival of patientsPathologic complete response rateUnited States Food and Drug Administration approvalRandomized phase III trialClinical trials of immunotherapyTreatment of non-small cell lung cancerFood and Drug Administration approvalImpairs surgical outcomesComplete response rateSignificant survival benefitTrials of immunotherapySurvival of patientsDrug Administration approval